Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm
31. Mai 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for...
Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
21. Mai 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture...
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
10. März 2014 11:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
04. März 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
18. Juli 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Hemispherx Biopharma Gains Regulatory Approval in Latin America
26. Januar 2012 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos,...